Vaughan Nelson Investment Management L.P. Has $30.64 Million Stake in Avantor, Inc. (NYSE:AVTR)

Vaughan Nelson Investment Management L.P. decreased its position in Avantor, Inc. (NYSE:AVTR) by 52.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,198,359 shares of the company’s stock after selling 1,310,198 shares during the period. Vaughan Nelson Investment Management L.P.’s holdings in Avantor were worth $30,642,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of AVTR. Mariner LLC lifted its holdings in Avantor by 17.3% in the third quarter. Mariner LLC now owns 42,025 shares of the company’s stock valued at $886,000 after buying an additional 6,196 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Avantor by 170.4% during the third quarter. Tower Research Capital LLC TRC now owns 24,722 shares of the company’s stock valued at $521,000 after purchasing an additional 15,580 shares during the period. Bank of Nova Scotia raised its holdings in shares of Avantor by 18.1% during the third quarter. Bank of Nova Scotia now owns 16,024 shares of the company’s stock valued at $338,000 after purchasing an additional 2,455 shares during the period. Glenmede Trust Co. NA raised its holdings in shares of Avantor by 300.1% during the third quarter. Glenmede Trust Co. NA now owns 139,143 shares of the company’s stock valued at $2,933,000 after purchasing an additional 104,362 shares during the period. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Avantor during the third quarter valued at about $16,864,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Trading Down 0.9 %

Shares of AVTR stock opened at $20.58 on Wednesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.05 and a current ratio of 1.61. The company has a market capitalization of $13.98 billion, a price-to-earnings ratio of 52.77, a PEG ratio of 2.15 and a beta of 1.32. Avantor, Inc. has a 52-week low of $16.63 and a 52-week high of $26.16. The company has a 50-day simple moving average of $23.66 and a two-hundred day simple moving average of $23.81.

Avantor (NYSE:AVTR) last posted its quarterly earnings data on Friday, April 26th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.20 by $0.02. The firm had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.68 billion. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. Research analysts anticipate that Avantor, Inc. will post 1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AVTR. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a report on Thursday, April 18th. Robert W. Baird dropped their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th. Evercore ISI dropped their price objective on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Barclays dropped their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Avantor presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.29.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.